Exscientia Bags Roche As AI Partner And $26m Series B To Fund Own Pipeline
Executive Summary
Exscientia's top executives tell Scrip why Roche opted for its AI insights - and how the UK group will use a $26m series B financing to build its proprietary pipeline.
You may also be interested in...
Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron
Sanofi and Regeneron terminate the immuno-oncology partnership signed in 2015, but will continue to collaborate on Libtayo. Biogen signs a pair of partnerships in CNS disorders, with C4 and Skyhawk, and more deals from the first day of the J.P. Morgan conference.
Finance Watch: Former Juno Execs Launch Sana With Allogeneic Cell Therapy Platform
Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.
Evotec Invests €15m In AI-driven Exscientia
Evotec has deepened its relationship with artificial intelligence company Exscientia by investing €15m in the UK-based company; the CRO wants to build on the pair's existing collaboration in immuno-oncology and use its stake to diversify the AI firm's portfolio.